Abstract 4845
Background
Outpatient palliative care (OPC) offers improved symptom control, quality of life and even survival. OPC clinics may be embedded in the oncology clinic or independent. We herein present our experience with an embedded OPC clinic led by a medical oncologist, an internist and a nurse in Hacettepe University Medical Oncology Clinic.
Methods
Patients who were referred by their oncologist or those who had severe symptoms and applied without referral were admitted. Besides baseline history and physical exam, Edmonton Symptom Assesment Scale (ESAS), Nutritional risk screening 2002 and visual analog scale for pain were routinely assessed except for patients with acute symptoms requiring urgent intervention. Interventions and consultations were recorded for all patients.
Results
A total of 174 patients were seen in our clinic within the first 5 months. Demographic features are shown in the table. The chief complaints were pain (26%), nausea and vomiting (13%) and decreased feeding (9%). Besides their chief complaints, patients had a median of 4 (min 0- max 8) other severe (ESAS score of > 5) complaints. The most frequent interventions were intravenous hydration, analgesic and/or antiemetic administration and prescription (n = 66), nutritionist (n = 62) and pain specialist (n = 59) consultations. Thirty-three patients (19 %) were referred for immediate hospitalization. The overall mortality within the first 30 days after the first OPC visit was 17%.Table:
1615P Baseline characteristics of the applied patients
Median Age (minimum- maximum) | 60.5 (17-91) |
Male/Female | 94 (58%)/80 (42%) |
Patient Stages | Stage 1: 4 (2.3%) Stage 2: 7 (4%) Stage 3: 18 (10.3%) Stage 4: 157 (73.6%) |
ECOG Performance Status | ECOG 0: 19 (10.9%) ECOG 1: 50 (28.7%) ECOG 2: 36 (20.7%) ECOG 3: 40 (23%) ECOG 4: 25 (14.4%) |
Tumor Sites | Gastrointestinal: 53 (30.5%) Lung: 43 (24.7%) Genitourinary: 15 (8.6%) Breast: 14 (8%) Gynecologic: 11 (6.3%) Head and Neck Cancer: 9 (5.2%) Other: 29 (16.7%) |
Conclusions
Our initial experience with the embedded OPC clinic mostly included patients with advanced disease, multiple severe symptoms and high risk of mortality. Management of these patients within the oncology clinic may address palliative care needs of these patients, provide timely therapeutic interventions, reduce unnecessary diagnostic tests and diminish emergency department applications by these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
2185 - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Presenter: Wolfgang Brückl
Session: Poster Display session 1
Resources:
Abstract
1524 - Effectiveness of sequencing TKIs in patients with EGFR mutation-positive Non-small-Cell Lung Cancer (NSCLC): A French National medico administrative claim database analysis
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
5733 - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Presenter: Tae Min Kim
Session: Poster Display session 1
Resources:
Abstract
5440 - Different stories for different EGFR exon 19 deletion variants
Presenter: Chao Zhao
Session: Poster Display session 1
Resources:
Abstract
2982 - Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy
Presenter: Yuan-Kai Shi
Session: Poster Display session 1
Resources:
Abstract
4002 - Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study
Presenter: Maximilian Hochmair
Session: Poster Display session 1
Resources:
Abstract
2941 - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network
Presenter: Julia Roeper
Session: Poster Display session 1
Resources:
Abstract
4154 - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Presenter: Matteo Canale
Session: Poster Display session 1
Resources:
Abstract
1175 - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Presenter: Kimio Yonesaka
Session: Poster Display session 1
Resources:
Abstract